Edition:
United Kingdom

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.67USD
13 Jul 2018
Change (% chg)

$0.03 (+1.83%)
Prev Close
$1.64
Open
$1.65
Day's High
$1.67
Day's Low
$1.64
Volume
45,416
Avg. Vol
191,707
52-wk High
$2.55
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Durect Announces Amendment To Licensing Agreement With Sandoz
Wednesday, 9 May 2018 

May 9 (Reuters) - DURECT Corp ::DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE).DURECT CORP - DURECT IS NOW ELIGIBLE FOR UP TO $30 MILLION IN MILESTONE PAYMENTS BASED ON NDA APPROVAL.DURECT CORP - EACH PARTY, PURSUANT TO AMENDMENT, IS ALSO PERMITTED TO DEVELOP OR COMMERCIALIZE COMPETING PRODUCTS.DURECT CORP - PURSUANT TO AMENDED AGREEMENT, DURECT REMAINS ELIGIBLE FOR UP TO AN ADDITIONAL $230 MILLION IN SALES-BASED MILESTONES.DURECT - PURSUANT TO AMENDED AGREEMENT, THERE IS NEW TERMINATION FEE PAYABLE TO DURECT IN EVENT THAT SANDOZ TERMINATES AGREEMENT FOR CONVENIENCE.DURECT CORP - AMENDMENT ALSO INCLUDES MODIFICATIONS TO DURECT'S DEVELOPMENT OBLIGATIONS AND TO BOTH PARTIES' TERMINATION PROVISIONS.DURECT CORP - DURECT HAS RIGHT TO TERMINATE FOR CONVENIENCE PRIOR TO NDA APPROVAL.  Full Article

Durect reports Q3 earnings per share of ‍$0.04​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Durect Corp :Durect Corporation announces third quarter 2017 financial results and provides corporate update.Q3 revenue $20.7 million.Q3 revenue view $3.7 million -- Thomson Reuters I/B/E/S.Quarterly earnings per share ‍$0.04​.  Full Article

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.  Full Article

Durect Corp qtrly loss per share $0.07
Monday, 1 Aug 2016 

Durect Corp : Durect corporation announces second quarter 2016 financial results and update of programs . Q2 revenue $3.2 million versus i/b/e/s view $3.7 million . Qtrly loss per share $0.07 .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz

* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)